[Incidence of highly malignant immunoblastic non-Hodgkin lymphoma in patients with Hodgkin's disease in remission]. 1985

L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011882 Radiotherapy, High-Energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle. Megavolt Radiotherapy,High-Energy Radiotherapy,Radiotherapy, Megavolt,High Energy Radiotherapy,Radiotherapy, High Energy
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000008 Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN. Abdominal Neoplasm,Neoplasm, Abdominal,Neoplasms, Abdominal
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
January 1983, Nederlands tijdschrift voor geneeskunde,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
November 1978, Die Medizinische Welt,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
February 1994, Leukemia & lymphoma,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
January 2005, Human pathology,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
February 1993, Der Internist,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
January 1983, Nouvelle revue francaise d'hematologie,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
January 1996, Zentralblatt fur Gynakologie,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
March 2000, European journal of haematology,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
February 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology,
L István, and L Balázs, and F Brittig, and K Pócza, and M Szentcsiki, and F Brenner
July 1990, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!